GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Debt-to-EBITDA

Roche Holding AG (Roche Holding AG) Debt-to-EBITDA : 2.16 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Roche Holding AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Roche Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5,424 Mil. Roche Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $30,170 Mil. Roche Holding AG's annualized EBITDA for the quarter that ended in Dec. 2023 was $16,482 Mil. Roche Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Roche Holding AG's Debt-to-EBITDA or its related term are showing as below:

RHHBY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.67   Med: 1.26   Max: 1.66
Current: 1.66

During the past 13 years, the highest Debt-to-EBITDA Ratio of Roche Holding AG was 1.66. The lowest was 0.67. And the median was 1.26.

RHHBY's Debt-to-EBITDA is ranked better than
50.23% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs RHHBY: 1.66

Roche Holding AG Debt-to-EBITDA Historical Data

The historical data trend for Roche Holding AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Debt-to-EBITDA Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.72 0.67 1.46 1.27 1.66

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.05 1.73 1.11 2.16

Competitive Comparison of Roche Holding AG's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Roche Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Debt-to-EBITDA falls into.



Roche Holding AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Roche Holding AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5424.376 + 30169.981) / 21438.483
=1.66

Roche Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5424.376 + 30169.981) / 16482.424
=2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Roche Holding AG  (OTCPK:RHHBY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Roche Holding AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus

Roche expands long-term alliance with Sysmex

By PRNewswire 08-03-2023